1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

By E. B. Villhauer, J. Brinkman, Goli B Naderi, B. Burkey, B. Dunning, K. Prasad, B. L. Mangold, M. E. Russell, T. Hughes. Journal of Medicinal Chemistry, 2003

610 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Endocrinology, Diabetes and Metabolism, Oncology

View Paper: https://www.semanticscholar.org/paper/de70ecd099254bac0a64bb72662ca263963d4d7b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Josephine M. Egan
2. Wook Kim

In Oncology

1. Josephine M. Egan
2. Wook Kim

Citations in the corpus

• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “However, the FDA requested additional data on patients with renal impairment before granting approval of vildagliptin, and Novartis has, at least for now, withdrawn its application from the FDA; it is approved for use by the European Medicines Agency.”